Neurohormonal targets in the treatment of pediatric heart failure

The history of the clinical approach to heart failure has been notable for a series of evolving conceptual paradigms, each in an effort to explain the clinical syndrome that presents. With the recent emphasis on a neurohormonal model of heart failure, we have seen the development of new therapeutic options that target biologically active molecules to preserve myocardial function. Sacubitril-valsartan, a combined angiotensin-neprilysin inhibitor shows the greatest clinical promise, while there is less evidence to support the use of recombinant relaxin-2 or vasopressin antagonists.

Source: Progress in Pediatric Cardiology - October 10, 2017 Category: Cardiology Authors: Jonathan B. Edelson, Joseph W. Rossano Tags: Review Source Type: research